Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Finn, AV; Oh, JS; Hendricks, M; Daher, M; Cagliero, E; Byrne, RM; Nadelson, J; Crimins, J; Kastrati, A; Schömig, A; Bruskina, O; Palacios, I; John, MC; Gold, HK 
Titel:
Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo. 
Abstract:
BACKGROUND: Type 2 diabetics (DM2) are at increased risk for restenosis as well as nonculprit coronary artery lesion (NCCL) progression. Rosiglitazone (RSG) favorably modifies many of the altered biologic processes in DM2, although recent reports have questioned its safety. We conducted a double-blind randomized trial to assess the effects of RSG versus placebo on in-stent late lumen loss (LL) and angiographic progression of NCCL. METHODS: A total of 65 DM2 were randomized to RSG (4 mg/d) (n = 3...    »
 
Zeitschriftentitel:
Am Heart J 
Jahr:
2009 
Band / Volume:
157 
Heft / Issue:
Seitenangaben Beitrag:
383.e1-8 
Sprache:
eng 
Print-ISSN:
0002-8703 
TUM Einrichtung:
I. Medizinische Klinik und Poliklinik